Stuttering Therapeutics Market Projected to Gain Significant Value through 2033

The global Stuttering Therapeutics Market is estimated to generate a market value of US$ 43 Million in 2023 and a market value of US$ 159.41 Million by 2033, with a CAGR of 14% from 2023 to 2033. In the historical period 2018 to 2022, the market for Stuttering Therapeutics grew at a CAGR of 11%.

The market for stuttering therapeutics refers to pharmaceuticals, therapies, and devices used to treat stuttering, a speech disorder characterised by involuntary repetitions or prolongations of sounds, syllables, or phrases, as well as pauses or blocks in speech.

The global stuttering therapeutics market is predicted to expand significantly in the future years, owing to increased awareness of the illness, an expanding patient population, and breakthroughs in research and development of new treatments.

Several treatments for stuttering are currently accessible, including antipsychotics, antidepressants, and anticonvulsants. These drugs, however, have not been specifically authorised by the FDA for the treatment of stuttering and may have serious negative effects.

The most common and successful treatment for stuttering is speech therapy, which involves teaching patients ways to enhance fluency and communication. Other therapies, such as cognitive-behavioral therapy and hypnosis, have had some success.

There are also a variety of technologies available to help with stuttering, such as electronic fluency devices, which use changed auditory input to promote speech fluency.

Major Players

Major players in the market include companies such as Competition Deep Dive, Auspex Pharmaceuticals, Inc., GlaxoSmithKline plc., Johnson & Johnson Services, Merck & Co., Inc., Pfizer Inc., Siemens Healthcare GmbH, Novartis AG, AstraZeneca, AbbVie Inc. along with healthcare providers and technology companies among other global players.

Key Segments Profiled in the Stuttering Therapeutics Industry Survey

Treatment:

  • Speech therapy
  • Stuttering Devices
  • Cognitive behavioural therapy
  • Parent-child interaction
  • Drug therapy

Type:

  • Developmental stuttering
  • Neurogenic stuttering

End User:

  • Hospitals
  • Specialty Clinics
  • Homecare

Comments

Post a Comment

Popular posts from this blog

Targeted Therapies for Sandhoff Disease | Assessing the Global Market Landscape

Image
The global Sandhoff Disease Therapeutics Market Size is expected to be worth US$ 10 million in 2023 and US$ 17.91 million by 2033, with a CAGR of 6% from 2023 to 2033. From 2018 to 2022, the Sandhoff Disease Treatments market increased at a 4% CAGR. According to the most recent studies, Sandhoff sickness is a rare disorder that affects 1 in 1,000,000 people. The rising demand for these medications is projected to spur the discovery of novel therapies, propelling the market forward in the coming years. Gene therapy is being investigated as a potential treatment for Sandhoff disease. The therapy restores the ability to break down GM2 ganglioside by delivering a functional copy of the missing enzyme into the patient's cells. This has the potential to reduce or stop disease progression while also improving patient quality of life. Key Takeaways from the Market Study   The Sandhoff Disease Therapeutics market increased at a 4% CAGR from 2018 to 2022. From 2023 to 2033, the global Sandh
Read more

A Safer Tomorrow | Emerging Trends in Hospital-Acquired Infection Control Market

Image
According to Future Market Insights' recently released Hospital-acquired Infection Control Market analysis report, global Hospital-acquired Infection Control sales in 2023 are expected to be US$ 6.5 billion. The market is expected to increase at a CAGR of 7% between 2023 and 2033, reaching $12.7 billion by 2033. Hospitals and intensive care units are predicted to create significant income in the market, with a CAGR of 7.6%. The occurrence of hospital-acquired infections, increasing proportion of surgical procedures, growing geriatric population and increasing prevalence of chronic diseases, technological advancements in sterilisation equipment, and growing awareness of environmental and personal hygiene are the key factors driving the Hospital-acquired infection control market. The increased use of e-beam sterilisation, as well as the reintroduction of ethylene oxide sterilisation, is predicted to increase demand for hospital-acquired infection management. The percentage of treatm
Read more

Transforming Trauma | Emerging Therapies and Interventions in Post-Traumatic Stress Disorder Treatment Market

Image
According to Future Market Insights, the Post-Traumatic Stress Disorder (PTSD) Treatment Market Sales would grow at a 5% CAGR between 2023 and 2033. By 2033, the global market for post-traumatic stress disorder (PTSD) therapy is expected to reach US$ 27.37 billion. The market's growth might be attributed to the increased prevalence of PTSD globally. According to the National Centre for PTSD, approximately 7-8% of the US population will develop PTSD at some point in their lives, with greater percentages among military veterans and persons who have experienced sexual assault or other types of trauma. The COVID-19 pandemic has also been highlighted as a possible cause of PTSD, with healthcare workers, first responders, and people immediately impacted by the virus being especially vulnerable. In addition, there is a growing emphasis on using digital therapies and other non-pharmacological techniques to treat PTSD. For example, virtual reality exposure treatment (VRET) has shown potent
Read more